Please login to the form below

Not currently logged in
Email:
Password:

Takeda UK launches new Prostap format

Takeda has launched a simpler, more efficient presentation of its prostate cancer and endometriosis treatment

Takeda UK has launched its prostate cancer and endometriosis and uterine fibroids treatment Prostap DCS (leuprorelin acetate) in a dual chamber pre-filled syringe.

The company said that the latest syringe offers a simplified, intuitive and efficient delivery system compared to the original Prostap vial and syringe mechanism.

Raj Persad, consultant urologist, Bristol Royal Infirmary and Southmead Hospital commented "Leuprorelin acetate has proved to be an efficacious treatment for prostate cancer for many years. An accurate and user-friendly delivery system can only be a positive step forward, particularly as administration is more efficient and therefore saves time. This can result in a better standard of care for patients as more time is spent providing much needed support and advice."

Prostap DCS delivers the same active ingredient and will be available in the same doses as existing presentations: one-month Prostap SR DCS (depot injection 3.75mg) and three-month Prostap 3 DCS (depot injection 11.25mg).

Prostap will not be available after October 2011.

6th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics